MEETING, Pa., Aug. 30, 2022 /PRNewswire/ -- INOVIO
(NASDAQ:INO), a biotechnology company focused on developing and
commercializing DNA medicines to help protect people from
infectious diseases and treat people with cancer and HPV-associated
diseases, today announced that Jacqueline
Shea, Ph.D., President and
CEO, will present at the H.C. Wainwright 24th Annual
Global Investment Conference.
H.C. Wainwright 24th Annual Global Investment
Date: Monday, September
Time: Available on-demand starting at 7:00
During the conference, Dr. Shea and members of INOVIO's
management team will conduct one-on-one meetings with
A webcast of the presentation will be available on the INOVIO
Investor Relations Events page at
replay of the webcast will be available for 90 days after the date
of the presentation.
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
infectious diseases, cancer, and diseases associated with HPV. Our
DNA medicines in development are delivered using our
investigational proprietary smart device to produce immune
responses against targeted pathogens and cancers. For more
information, visit www.inovio.com.
Investors & Media:
Gene Kim, (267) 589-9471,
Thomas Hong, (267) 440-4298,
SOURCE INOVIO Pharmaceuticals, Inc.